Retevmo selpercatinib logo
  • House For Patients
    • Understanding RET
    • How Retevmo Works
    • Retevmo in NSCLC
    • Retevmo in Thyroid Cancer
    • Taking Retevmo
    • Savings & Support
      • Savings & Support
      • Retevmo Savings Card
      • Retevmo Ongoing Support
      • Filling Your Prescription
      • Support Groups
  • For Healthcare Providers
    • Efficacy
    • Safety & Tolerability
    • Dosing
    • Savings & Support
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Expand contact lilly

Savings* & Support

See how you can save on Retevmo and get support along the way

Savings card icon

Retevmo Savings Card

Eligible commercially insured covered patients pay as little as $0 a month*

Paying for treatment shouldn’t be an additional concern for you and your loved ones, so we’ve created the Retevmo Savings Card, which may help you manage treatment costs.

Need a Savings Card?

Download savings card

Already have a Savings Card? Activate Savings Card

*Offer good for up to 12 months until 12/31/2021. Patients must have coverage for Retevmo through their commercial drug insurance to pay as little as $0 for a 30-day supply of Retevmo, subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $25,000 maximum annual cap. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

We will need your HIPAA authorization to work on your behalf to help you pay as little as possible. We believe that by you taking a little extra time now to provide HIPAA authorization, we can help you pay as little as possible for your Retevmo medication. Requesting a Retevmo savings card shouldn’t take more than a few minutes. If you do not want to provide HIPAA authorization online, please contact the Lilly Oncology Support Center at 1-866-472-8663, Monday-Friday, 8 am–10 pm ET to request a savings card.

As a reminder, HIPAA is the Health Insurance Portability and Accountability Act that provides data privacy and security to protect your health information.

Retevmo Ongoing Support

We are here for you.

Whether you have questions about Retevmo or just need someone to talk to, your Companion in Care™ is here for you.

Patient support program icon

Sign up to connect with a dedicated Companion in Care, who will provide personalized phone support throughout your treatment by:

  • Helping to get you started on Retevmo quickly
  • Focusing on the insurance process, so you can focus on treatment
  • Being there to answer questions or just lend an ear
  • Connecting you with resources and information

There are 3 simple ways to join:

  • Enroll now
  • Call the Lilly Oncology Support Center at 1-866-472-8663
  • Ask a member of your healthcare team about signing up

Retevmo Companion in Care call agents are not medical professionals. Your doctor is your source for medical advice.

Filling Your Prescription

There are multiple ways to get Retevmo, depending on your insurance.

Specialty pharmacy icon

Specialty Pharmacy

Doctor icon

Your Doctor

Hospital health system icon

Your Hospital

Here’s how a specialty pharmacy works with you to fill your Retevmo prescription:

  • Your doctor sends your prescription to a specialty pharmacy
  • The specialty pharmacy will call you to schedule a date and time to deliver your Retevmo medication (you may not recognize the phone number)
  • The specialty pharmacy can also help assess your eligibility for the Retevmo Savings Card*

Your Retevmo Companion in Care can help you find the specialty pharmacy with the lowest out-of-pocket cost

Governmental beneficiaries excluded, see above terms and conditions.

Support Groups

Connect with others in your community who understand your diagnosis.

It's important to remember that there are many people in the same place as you – people who understand what you are going through. You are not alone on this cancer journey. There are organizations that can connect you with opportunities and support.‡

Lung cancer advocacy organizations

American Lung Association and Lung Force logos

American Lung Association® is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. The Lung Association is committed to defeating lung cancer and supporting those affected by it.

Go2 Foundation for Lung Cancer logo

GO2 Foundation for Lung Cancer® transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

Lungevity logo

LUNGevity Foundation®, the nation's leading lung cancer-focused nonprofit, is committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease.

Thyroid cancer advocacy organizations

Thanc Foundation logo

The THANC (Thyroid, Head and Neck Cancer) Foundation is an international, independent nonprofit dedicated to supporting research and education in the early detection and treatment of thyroid, head and neck cancers. THANC is actively committed to advancing new therapies and alleviating the suffering and functional impairment of patients who undergo treatment. The THANC Guide is a significant resource that endeavors to help patients through their cancer journey.

ThyCa: Thyroid Cancer Survivors' Association logo

ThyCa: Thyroid Cancer Survivors’ Association, Inc., an international nonprofit organization advised by thyroid cancer specialists, educates and supports patients and families through its comprehensive website, support groups, person-to-person support, free newsletter and downloadable handbooks and low-iodine cookbook, available in numerous languages. ThyCa sponsors seminars, workshops, and an annual international 3-day conference, as well as Thyroid Cancer Awareness Month, year-round awareness programs for early detection, and thyroid cancer research funds and research grants.

‡This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party organization names and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this material.

Important Facts About RETEVMO® (reh-TEHV-moh). It is also known as selpercatinib.

RETEVMO is a prescription medicine that is used to treat certain cancers caused by an abnormal gene, called RET, in:

  • adults with non-small cell lung cancer (NSCLC) that has spread.
  • adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who need a medicine that can be taken by mouth or injection.
  • adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread, who need a medicine that can be taken by mouth or injection, and who have received radioactive iodine and it did not work or is no longer working.

Your doctor will perform a test to make sure that RETEVMO is right for you.

It is not known if RETEVMO is safe and effective in children younger than 12 years of age.

Warnings

RETEVMO may cause serious side effects, including:

Liver problems: Liver problems (higher levels of liver enzymes) are common with RETEVMO and may sometimes be serious. Your doctor will do blood tests before and during treatment with RETEVMO to check for liver problems. Tell your doctor right away if you get any of the following symptoms of liver problems during treatment:

  • yellowing of your skin or the white part of your eyes (jaundice)
  • dark, “tea-colored” urine
  • sleepiness
  • bleeding or bruising
  • loss of appetite
  • nausea or vomiting
  • pain on the upper right side of your stomach area

If you develop liver problems while taking RETEVMO, your doctor may lower your dose, stop treatment for a while, or stop treatment permanently.

High blood pressure (hypertension): High blood pressure is common with RETEVMO. It may sometimes be serious. You should check your blood pressure regularly during treatment with RETEVMO. Tell your doctor if you get any of the following symptoms during treatment:

  • confusion
  • headaches
  • shortness of breath
  • dizziness
  • chest pain

Heart rhythm changes (QT prolongation) can happen. These may be serious. RETEVMO may cause very slow, very fast, or irregular heartbeats. Tell your doctor right away if you get any of the following symptoms during treatment:

  • loss of consciousness
  • fainting
  • dizziness
  • a change in the way your heart beats (heart palpitations)

Bleeding problems: RETEVMO can cause bleeding, which can be serious and may lead to death. Tell your doctor if you have any signs of bleeding during treatment, including:

  • vomiting blood or if your vomit looks like coffee-grounds
  • pink or brown urine
  • red or black stools that look like tar
  • coughing up blood or blood clots
  • unusual bleeding or bruising of your skin
  • menstrual bleeding that is heavier than normal
  • unusual vaginal bleeding
  • nose bleeds that happen often
  • drowsiness or difficulty being woken up
  • confusion
  • headache
  • change in speech

Allergic reactions: RETEVMO can cause a fever, rash, or pain in muscles or joints, especially in the first month of treatment. Tell your doctor if you get any of these symptoms. Your doctor may stop treatment for a while or lower your dose of RETEVMO.

Risk of wound healing problems: Wounds may not heal well during treatment with RETEVMO. Tell your doctor if you plan to have any surgery before or during treatment with RETEVMO.

  • You should stop taking RETEVMO at least 7 days before planned surgery.
  • Your doctor should tell you when you may start taking RETEVMO again after surgery.

Common side effects

The most common side effects of RETEVMO are:

  • higher levels of liver enzymes
  • higher blood sugar levels
  • lower white blood cell count
  • lower protein (albumin) levels in the blood
  • lower calcium levels in the blood
  • dry mouth
  • diarrhea
  • higher creatinine levels (this measures kidney function)
  • high blood pressure
  • tiredness
  • swelling of your arms, legs, hands, and feet (peripheral edema)
  • lower platelet count
  • higher cholesterol levels
  • rash
  • lower salt (sodium) levels in the blood
  • constipation

RETEVMO may affect the ability to have children for both females and males. Talk to your doctor if you want to have children and you are thinking about starting treatment with RETEVMO.

  • RETEVMO can harm your unborn baby. You should not become pregnant during treatment with RETEVMO.
  • If you are able to become pregnant:
    • Your doctor will do a pregnancy test before you start treatment with RETEVMO.
    • You should use effective birth control (contraception) during treatment and for at least 1 week after the final dose of RETEVMO. Talk to your doctor about birth control methods that may be right for you.
    • Tell your doctor right away if you become pregnant or think you might be pregnant during treatment with RETEVMO.
  • Males with partners who are able to become pregnant should use effective birth control during treatment with RETEVMO and for at least 1 week after the final dose of RETEVMO.

These are not all the possible side effects with RETEVMO. If you are concerned about side effects, talk to your doctor. Tell your doctor about any side effects you have. You can also report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before taking RETEVMO, tell your doctor about all your medical conditions, including if you:

  • have liver problems
  • have high blood pressure
  • have heart problems, including a condition called QT prolongation
  • have bleeding problems
  • plan to have surgery. You should stop taking RETEVMO at least 7 days before your planned surgery.
  • are pregnant or plan to become pregnant. See section above for additional information.
  • are breastfeeding or plan to breastfeed. It is not known if RETEVMO passes into your breast milk. Do not breastfeed during treatment with RETEVMO and for 1 week after the last dose.

Also tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how RETEVMO works.

  • You should avoid taking certain medicines when also taking RETEVMO. These include:
    • St. John’s wort,
    • proton-pump inhibitors (PPIs) such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, and rabeprazole,
    • H2 blockers such as famotidine, nizatidine, and cimetidine,
    • antacids that contain aluminum, magnesium, calcium, simethicone, or buffered medicines.

If you cannot avoid taking PPIs, H2 blockers, or antacids, see the “How to take with certain other medicines” section below for more information. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How to take RETEVMO

  • Take RETEVMO exactly as your doctor tells you.
  • Your doctor may stop treatment or change your dose of RETEVMO if you have side effects. Do not change your dose or stop taking RETEVMO unless your doctor tells you.
  • Swallow RETEVMO capsules whole. Do not chew or crush the capsules.
  • RETEVMO is taken by mouth, usually 2 times a day with or without food.
  • RETEVMO doses should be taken 12 hours apart.
  • If you vomit after taking a dose of RETEVMO, do not take an extra dose. Take the next dose of RETEVMO at your scheduled time.
  • Do not take a missed dose of RETEVMO unless it is more than 6 hours until your next scheduled dose.
  • If you take too much RETEVMO, call your doctor or go to the nearest hospital emergency room right away.

How to take RETEVMO with certain other medicines

  • If you take a PPI (such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, or rabeprazole), take RETEVMO with food.
  • If you take an antacid that contains aluminum, magnesium, calcium, simethicone, or buffered medicines, take RETEVMO 2 hours before or 2 hours after taking the antacid.
  • If you take an H2 blocker (such as famotidine, nizatidine, or cimetidine), take RETEVMO 2 hours before or 10 hours after taking the H2 blocker.

Learn more

For more information, call 1-800-545-5979.

This summary provides basic information about RETEVMO. It does not include all information known about this medicine. Read the information that comes with your medicine each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other health care provider about RETEVMO and how to take it. Your doctor is the best person to help you decide if RETEVMO is right for you.

RETEVMO® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

SE CON BS 17NOV2020

Prescribing Information
Patient Prescribing Information
Terms of Use
Privacy Statement
Accessibility Statement
Sitemap
Need assistance?
Call 1-800-545-5979

This site is intended for US residents aged 18 or older.

Retevmo® is a registered trademark and Companion in Care™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

PP-SE-US-0031 02/2021 ©Lilly USA, LLC 2021. All rights reserved.

Terms of Use Privacy Statement Accessibility Statement Sitemap
Lilly